Thermo Fisher Scientific Inc. $TMO Shares Sold by Hartford Investment Management Co.

Hartford Investment Management Co. reduced its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.1% in the 2nd quarter, Holdings Channel reports. The institutional investor owned 20,546 shares of the medical research company’s stock after selling 868 shares during the period. Hartford Investment Management Co.’s holdings in Thermo Fisher Scientific were worth $10,301,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the company. Matrix Asset Advisors Inc. NY grew its position in shares of Thermo Fisher Scientific by 22.7% in the 2nd quarter. Matrix Asset Advisors Inc. NY now owns 27,668 shares of the medical research company’s stock worth $13,872,000 after acquiring an additional 5,121 shares in the last quarter. WealthBridge Investment Counsel Inc. raised its position in shares of Thermo Fisher Scientific by 2.2% during the 2nd quarter. WealthBridge Investment Counsel Inc. now owns 12,852 shares of the medical research company’s stock valued at $6,443,000 after acquiring an additional 275 shares in the last quarter. Tompkins Financial Corp boosted its holdings in Thermo Fisher Scientific by 2.4% in the second quarter. Tompkins Financial Corp now owns 1,742 shares of the medical research company’s stock worth $873,000 after purchasing an additional 40 shares during the period. Keudell Morrison Wealth Management increased its stake in Thermo Fisher Scientific by 5.1% during the second quarter. Keudell Morrison Wealth Management now owns 498 shares of the medical research company’s stock valued at $250,000 after purchasing an additional 24 shares during the last quarter. Finally, Firethorn Wealth Partners LLC raised its holdings in shares of Thermo Fisher Scientific by 6.3% during the second quarter. Firethorn Wealth Partners LLC now owns 526 shares of the medical research company’s stock worth $264,000 after purchasing an additional 31 shares during the period. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $588.17 on Friday. The stock has a market cap of $217.48 billion, a price-to-earnings ratio of 31.64, a PEG ratio of 2.42 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The stock’s 50 day moving average price is $529.37 and its 200 day moving average price is $509.58.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. During the same period last year, the firm earned $4.28 EPS. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on TMO shares. Royal Bank Of Canada lifted their price target on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a “sector perform” rating in a report on Friday, July 24th. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $670.00 to $540.00 in a research note on Wednesday, June 3rd. Piper Sandler lifted their target price on Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a “neutral” rating in a research note on Monday, July 27th. Robert W. Baird lowered their target price on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $619.41.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 4,608 shares of the business’s stock in a transaction that occurred on Friday, August 7th. The shares were sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Lisa P. Britt sold 5,850 shares of the firm’s stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $580.00, for a total transaction of $3,393,000.00. Following the sale, the vice president owned 14,784 shares of the company’s stock, valued at $8,574,720. The trade was a 28.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.